Back to Search Start Over

Author Correction: Cellular and molecular synergy in AS01-adjuvanted vaccines results in an early IFNγ response promoting vaccine immunogenicity

Authors :
Katrijn Van Deun
David Franco
Stanislas Goriely
Catherine Collignon
Christopher J. Genito
Arnaud Didierlaurent
Margherita Coccia
Sheetij Dutta
Norman C. Waters
Age K. Smilde
Mary J. van Helden
Patricia Bourguignon
Caroline Hervé
Sandra Morel
Bart N. Lambrecht
Sophie Detienne
Robbert van der Most
Robert A. van den Berg
Aurélie Chalon
Nathalie Garçon
Iain Welsby
Source :
npj Vaccines, Vol 3, Iss 1, Pp 1-1 (2018), NPJ Vaccines
Publication Year :
2018
Publisher :
Nature Publishing Group, 2018.

Abstract

Combining immunostimulants in adjuvants can improve the quality of the immune response to vaccines. Here, we report a unique mechanism of molecular and cellular synergy between a TLR4 ligand, 3-O-desacyl-4’-monophosphoryl lipid A (MPL), and a saponin, QS-21, the constituents of the Adjuvant System AS01. AS01 is part of the malaria and herpes zoster vaccine candidates that have demonstrated efficacy in phase III studies. Hours after injection of AS01-adjuvanted vaccine, resident cells, such as NK cells and CD8+ T cells, release IFNγ in the lymph node draining the injection site. This effect results from MPL and QS-21 synergy and is controlled by macrophages, IL-12 and IL-18. Depletion strategies showed that this early IFNγ production was essential for the activation of dendritic cells and the development of Th1 immunity by AS01-adjuvanted vaccine. A similar activation was observed in the lymph node of AS01-injected macaques as well as in the blood of individuals receiving the malaria RTS,S vaccine. This mechanism, previously described for infections, illustrates how adjuvants trigger naturally occurring pathways to improve the efficacy of vaccines.<br />Adjuvants: Vaccine components working in synergy to improve beneficial effects of vaccination A mechanism is revealed by which vaccine components co-operate to stimulate the immune system and improve vaccine efficacy. Some vaccines are formulated with adjuvants—compounds that induce a greater immune response to the vaccine and help to elicit greater protection against future infections. Arnaud Didierlaurent and his team of researchers at GSK Vaccines, Belgium, demonstrate that the two immunostimulants in the adjuvant AS01, used in several recently developed vaccines, works in tandem to trigger the activation of important immune system moderators. The synergistic effect of the immunostimulants modulate specific immune cells at the site of the vaccination to better prepare the body against future infection. Studies such as this allow us to better understand how vaccines work and lay the foundation for more informed research into future vaccine development.

Details

Language :
English
ISSN :
20590105
Volume :
3
Issue :
1
Database :
OpenAIRE
Journal :
npj Vaccines
Accession number :
edsair.doi.dedup.....2ecf3f1808031d1a66ab82978c708016
Full Text :
https://doi.org/10.1038/s41541-018-0047-7